Judy Walczak

Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.

Peter J. O’Dwyer, Angela Paul, Judy Walczak et al. · Journal of Clinical Oncology · 1990 · 99 citations

Tumor Biology, Oncology, Gastrointestinal Oncology +15

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

Naomi B. Haas, F P LaCreta, Judy Walczak et al. · PubMed · 1994 · 85 citations

Pharmaceutical Science, 24-Hour Continuous Infusion, Oncology +15

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.

Séamus O’Reilly, Gini F. Fleming, Shannon Barker et al. · Journal of Clinical Oncology · 1997 · 64 citations

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

Elizabeth Rosyold, Russell J. Schilder, Judy Walczak et al. · Cancer Chemotherapy and Pharmacology · 1992 · 24 citations

Oncology, Phase Ii Trial, Gastrointestinal Oncology +7

Phase I Trial Of Fluorouracil Modulation by N-Phosphonacety-L-aspartate and 6-Methylmercaptopurine Riboside: Optimization of 6-Methylmercaptopurine Riboside Dose and Schedule Through Biochemical Analysis of Sequential Tumor Biopsy Specimens

Peter J. O’Dwyer, GaryR. Hudes, Joseph Colofiore et al. · JNCI Journal of the National Cancer Institute · 1991 · 17 citations